Amid reports of blood clots in patients after getting AstraZeneca COVID-19 shot, Australian officials on Saturday said that the country will continue the usage of the AstraZeneca vaccine. The concerns were raised after a 44-year old Australian man reportedly with blood clotting was admitted to the hospital days after getting the jab, reported Reuters.

Also Read| Family files complaint after French woman dies post AstraZeneca shot

The Therapeutic Goods Administration (TGA) regulator and Australian Technical Advisory Group on Immunisation (ATAGI), after conducting a meeting with health experts panel to discuss the issue, concluded that the drug will not be blocked until further notice.

“ATAGI or TGA have not advised us to pause the usage of AstraZeneca vaccine in Australia,” said deputy chief medical officer Michael Kidd in a press briefing.

Also Read| France to close schools, go into limited lockdown amid surging COVID cases

Kidd, however, also said that the blood clotting case reported in the country is likely to be associated with the vaccine.

AstraZeneca has been under keen scrutiny of global health regulators and several European countries after reports of serious serious thrombosis started doing rounds in people who were administered the drug.

These concerns led to various European countries including France, Denmark and Germany with many others blocked the usage of the drug.

Also Read| EU regulator says AstraZeneca is safe, conducting further analysis

For the unversed, Thrombosis is a condition that prevents normal blood from flowing through the circulatory system due to clots.

At least 30 such Thrombosis cases and 7 deaths were reported in UK so far as the aggrieved suffered blood clots due to the Oxford-AstraZeneca vaccine.

AstraZeneca on the other hand released a statement last month following US efficiency trials saying that its vaccine is 79% effective at preventing the disease and does not increase the risk of blood clots.